Current pharmacotherapeutic concepts for the treatment of obesity in adults

Therapeutic Advances in Cardiovascular Disease

Volumn 3, Issue 1, 2009, Pages 75-90

  Idelevich, Evgeny ^a   Kirch, Wilhelm ^a   Schindler, Christoph ^a  

^a DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

Drug therapy; Obesity; Orlistat; Rimonabant; Sibutramine

Indexed keywords

ADIPONECTIN; AMIODARONE; ANTIHYPERTENSIVE AGENT; ANTIOBESITY AGENT; CYCLOSPORIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN; VITAMIN K GROUP;

ABNORMAL FECES COMPOSITION; ADIPONECTIN BLOOD LEVEL; ANXIETY DISORDER; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DEFECATION DISORDER; DEFECATION URGENCY; DEPRESSION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DIET THERAPY; DIZZINESS; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; INSOMNIA; MONOTHERAPY; MOOD DISORDER; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OILY STOOL; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULSE RATE; RECOMMENDED DRUG DOSE; REVIEW; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SINGLE DRUG DOSE; STEATORRHEA; SUICIDAL IDEATION; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT REDUCTION; XEROSTOMIA;

ADULT; ANTI-OBESITY AGENTS; APPETITE DEPRESSANTS; COMBINED MODALITY THERAPY; CYCLOBUTANES; ENZYME INHIBITORS; HUMANS; LACTONES; LIPASE; OBESITY; PIPERIDINES; PREVALENCE; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RISK REDUCTION BEHAVIOR; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 68749091398     PISSN: 17539447     EISSN: None     Source Type: Journal    
DOI: 10.1177/1753944708098226     Document Type: Review

References (115)

1. Anderson, J.W., Konz, E.C., Frederich, R.C. and Wood, C.L. (2001) Long-term weight-loss maintenance: a meta-analysis of US studies. Am J Clin Nutr 74: 579-584.
2. Arterburn, D.E., Crane, P.K. and Veenstra, D.L. (2004) The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 164: 994-1003.
3. Astrup, A. and Rossner, S. (2000) Lessons from obesity management programmes: greater initial weight loss improves long-term maintenance. ObesRev 1: 17-19.
4. Bensaid, M., Gary-Bobo, M., Esclangon, A., Maffrand, J.P., Le Fur, G., Oury-Donat, F. et al. (2003) The cannabinoid CB 1 receptor antagonist SR 141716 increases Acrp 30 mRNA expression in adipose tissue of obese fa / fa rats and in cultured adipocyte cells. Mol Pharmacol 63: 908-914.
5. Bloom, S.R., Kuhajda, F.P., Laher, I., Pi-Sunyer, X., Ronnett, G.V., Tan, T.M. et al. (2008) The obesity epidemic: pharmacological challenges. Mol Interv 8: 82-98.
6. Bramlage, P., Boöcking, W. and Kirch, W. (2005) Die Blockade des Endocannabinoidsystems - Gewichtsreduktion und kardiovaskulaöres Risikomanagement. Dtsch Med Wochenschr 130: 665-668.
7. Bramlage, P., Pittrow, D., Wittchen, H.U., Kirch, W., Boehler, S., Lehnert, H. et al. (2004 a) Hypertension in overweight and obese primary care patients is highly prevalent and poorly controlled. Am J Hypertens 17: 904-910.
8. Bramlage, P., Wittchen, H.U., Pittrow, D., Kirch, W., Krause, P., Lehnert, H. et al. (2004 b) Recognition and management of overweight and obesity in primary care in Germany. Int J Obes Relat Metab Disord 28: 1299-1308.
9. Bray, G.A. and Ryan, D.H. (2007) Drug treatment of the overweight patient. Gastroenterology 132: 2239-2252.
10. Broom, I., Wilding, J., Stott, P. and Myers, N. (2002) Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK multimorbidity study. Int J Clin Pract 56: 494-499.
11. Cawthorne, M.A. (2007) Opportunities and challenges for the development of pharmacological therapies for obesity treatment. Obes Rev 8(Suppl. 1): 131-136.
12. Centers for Disease Control and Prevention. ( 1997) Cardiac valvulopathy associated with exposure to fenfluramine or dexfenfluramine: US Department of Health and Human Services Interim Public Health Recommendations, November 1997. MMWR Morb Mortal Wkly Rep 46: 1061-1066.
13. Christensen, R., Kristensen, P.K., Bartels, E.M., Bliddal, H. and Astrup, A. (2007) Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370: 1706-1713.
14. Clinicaltrials.gov (2008 a) Atherosclerosis Underlying Development assessed by Intima-media Thickness in patients On Rimonabant (AUDITOR), available at:
15. Clinicaltrials.gov (2008 b) Comprehensive Rimonabant Evaluation Study of Cardiovascular Endpoints and Outcomes (CRESCENDO). Available at:
16. Connolly, H.M., Crary, J.L., McGoon, M.D., Hensrud, D.D., Edwards, B.S., Edwards, W.D. et al. (1997) Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 337: 581-588.
17. Curioni, C. and Andre, C. (2006) Rimonabant for overweight or obesity. Cochrane Database Syst Rev: CD006162.
18. Davidson, M.H., Hauptman, J., Digirolamo, M., Foreyt, J.P., Halsted, C.H., Heber, D. et al. (1999) Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 281: 235-242.
19. Despres, J.P., Golay, A. and Sjostrom, L. (2005) Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 353: 2121-2134.
20. Di Marzo, M.V., Bifulco, M. and de Petrocellis, L. (2004) The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov 3: 771-784.
21. Dixon, J. (2006) Survival advantage with bariatric surgery: report from the 10th international congress on obesity. Surg Obes Relat Dis 2: 585-586.
22. Douketis, J.D., Macie, C., Thabane, L. and Williamson, D.F. (2005) Systematic review of long-term weight loss studies in obese adults: clinical significance and applicability to clinical practice. Int J Obes (Lond) 29: 1153-1167.
23. EMEA (2007 a) European Medicines Agency recommends acomplia must not be used in patients on antidepressants or with major depression. Press Release. Doc. Ref. EMEA/329826/2007, London, 19 July 2007. Available at:
24. EMEA (2007 b) Summary of product characteristics acomplia 20 mg film-coated tablets, 19 July 2007. Available at:
25. EMEA (2008 a) European Medicines Agency recommends first switch from prescription-only to non-prescription for a centrally authorised medicine. Press Release. Doc. Ref. EMEA/CHMP/493770/2008, London, 23. October 2008. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/alli/4937708en.pdf, accessed on 3 November 2008.
26. EMEA (2008 b) The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia. Press Release. Doc. Ref. EMEA/ CHMP/537777/2008, London, 23. October 2008. Available at: http://www.emea.europa.eu/humandocs/PDFs/EPAR/acomplia/53777708en.pdf, accessed on 3 November 2008.
27. FDA (2007 a) FDA approves orlistat for over-the-counter Use. Press release, 7 February 2007. Available at:
28. FDA (2007 b) US Food and Drug Administration Advisory Committee. FDA Briefing Document: NDA 21-888. Zimulti (Rimonabant) Tablets, 20 mg. Available at: < http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4306b1-FDA-backgrounder.pdf> ;, accessed on 9 June 2008.
29. FDA (2008) FDA Approved Obesity Drugs. Available at:
30. Finer, N., James, W.P., Kopelman, P.G., Lean, M.E. and Williams, G. (2000) One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord 24: 306-313.
31. Flegal, K.M., Carroll, M.D., Ogden, C.L. and Johnson, C.L. (2002) Prevalence and trends in obesity among US adults, 1999-2000. JAMA 288: 1723-1727.
32. Fong, T.M., Guan, X.M., Marsh, D.J., Shen, C.P., Stribling, D.S., Rosko, K.M. et al. (2007) Antiobesity efficacy of a novel cannabinoid-1 receptor inverse agonist, N-[(1s,2s)-3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl]-2-methyl-2 -[[5-(trifluoromethyl)pyridin-2-Yl]oxy]propanamide (Mk-0364), in rodents. J Pharmacol Exp Ther 321: 1013-1022.
33. Fontaine, K.R., Redden, D.T., Wang, C., Westfall, A.O. and Allison, D.B. (2003) Years of life lost due to obesity. JAMA 289: 187-193.
34. Garcia, S.B., Barros, L.T., Turatti, A., Martinello, F., Modiano, P., Ribeiro-Silva, A. et al. (2006) The anti-obesity agent orlistat is associated to increase in colonic preneoplastic markers in rats treated with a chemical carcinogen. Cancer Lett 240: 221-224.
35. Garrel, D. (2007) Alternative treatments for obesity. 2006 Canadian Clinical Practice Guidelines on the Management and Prevention of Obesity in Adults and Children. CMAJ 176: 76-78.
36. Goldstein, D.J. (1992) Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 16: 397-415.
37. Guy-Grand, B., Apfelbaum, M., Crepaldi, G., Gries, A., Lefebvre, P. and Turner, P. (1989) International trial of long-term dexfenfluramine in obesity. Lancet 2: 1142-1145.
38. Hanefeld, M. and Sachse, G. (2002) The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab 4: 415-423.
39. Hauner, H., Meier, M., Wendland, G., Kurscheid, T., Lauterbach, K. and Study, G. (2004) Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT study. Exp Clin Endocrinol Diabetes 112: 201-207.
40. Hauptman, J.B., Jeunet, F.S. and Hartmann, D. (1992) Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin). Am J Clin Nutr 55: 309S-313S.
41. Hollander, P.A., Elbein, S.C., Hirsch, I.B., Kelley, D., McGill, J., Taylor, T. et al. (1998) Role of orlistat in the treatment of obese patients with type 2 Diabetes. A 1-year randomized double-blind study. Diabetes Care 21: 1288-1294.
42. HOPE Study Investigators. (1996) The Hope (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin e in patients at high risk of cardiovascular events. Can J Cardiol 12: 127-137.
43. Hutton, B. and Fergusson, D. (2004) Changes in body weight and serum lipid profile in obese patients treated with orlistat in addition to a hypocaloric diet: a systematic review of randomized clinical trials. Am J Clin Nutr 80: 1461-1468.
44. Icsi (2006) Institute for Clinical Systems Improvement. Prevention and Management of Obesity (Mature Adolescents and Adults), 3rd edn, November 2006. Available at:
45. James, W.P., Astrup, A., Finer, N., Hilsted, J., Kopelman, P., Rossner, S. et al. (2000) Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Storm Study Group. Sibutramine trial of obesity reduction and maintenance. Lancet 356: 2119-2125.
46. Jordan, J., Scholze, J., Matiba, B., Wirth, A., Hauner, H. and Sharma, A.M. (2005) Influence of sibutramine on blood pressure: evidence from placebo-controlled trials. Int J Obes (Lond) 29: 509-516.
47. Kaya, A., Aydin, N., Topsever, P., Filiz, M., Ozturk, A., Dagar, A. et al. (2004) Efficacy of sibutramine, orlistat and combination therapy on short-term weight management in obese patients. Biomed Pharmacother 58: 582-587.
48. Kelley, D.E., Bray, G.A., Pi-Sunyer, F.X., Klein, S., Hill, J., Miles, J. et al. (2002) Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 25: 1033-1041.
49. Kim, S.H., Lee, Y.M., Jee, S.H. and Nam, C.M. (2003) Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials. Obes Res 11: 1116-1123.
50. Kopelman, P., Bryson, A., Hickling, R., Rissanen, A., Rossner, S., Toubro, S. et al. (2007) Cetilistat (ATL-962), a novel lipase inhibitor: a 12-week randomized, placebo-controlled study of weight reduction in obese patients. Int J Obes (Lond) 31: 494-499.
51. Lau, D.C., Douketis, J.D., Morrison, K.M., Hramiak, I.M., Sharma, A.M. and Ur, E. (2007) 2006 Canadian Clinical Practice Guidelines on the Management and Prevention of Obesity in Adults and Children. CMAJ 176: S1-117.
52. Lexchin, J. (2001) Lifestyle drugs: issues for debate. CMAJ 164: 1449-1451.
53. Li, Z., Maglione, M., Tu, W., Mojica, W., Arterburn, D., Shugarman, L.R. et al. (2005) Meta-analysis: pharmacologic treatment of obesity. Ann Intern Med 142: 532-546.
54. Lindgarde, F. (2000) The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: The Swedish multimorbidity study. J Intern Med 248: 245-254.
55. MacWalter, R.S., Fraser, H.W. and Armstrong, K.M. (2003) Orlistat enhances warfarin effect. AnnPharmacother 37: 510-512.
56. Mannucci, E., Dicembrini, I., Rotella, F. and Rotella, C.M. (2008) Orlistat and sibutramine beyond weight loss. Nutr Metab Cardiovasc Dis 18: 342-348.
57. Mason, J.M., Dickinson, H.O., Nicolson, D.J., Campbell, F., Ford, G.A. and Williams, B. (2005) The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension. J Hypertens 23: 1777-1781.
58. McDuffie, J.R., Calis, K.A., Booth, S.L., Uwaifo, G.I. and Yanovski, J.A. (2002) Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy 22: 814-822.
59. McMahon, F.G., Fujioka, K., Singh, B.N., Mendel, C.M., Rowe, E., Rolston, K. et al. (2000) Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial. Arch Intern Med 160: 2185-2191.
60. McNulty, S.J., Ur, E. and Williams, G. (2003) A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care 26: 125-131.
61. McTigue, K.M., Harris, R., Hemphill, B., Lux, L., Sutton, S., Bunton, A.J. et al. (2003) Screening and interventions for obesity in adults: summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 139: 933-949.
62. Melia, A.T., Koss-Twardy, S.G. and Zhi, J. (1996) The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol 36: 647-653.
63. Miles, J.M., Leiter, L., Hollander, P., Wadden, T., Anderson, J.W., Doyle, M. et al. (2002) Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 25: 1123-1128.
64. Mittendorfer, B., Ostlund, Jr. R.E., Patterson, B.W. and Klein, S. (2001) Orlistat inhibits dietary cholesterol absorption. Obes Res 9: 599-604.
65. NIH (2000) Practical Guide to the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults. National Institutes of Health. National Heart, Lung, and Blood Institute. NIH Publication No. 00-4084, October 2000. Available at:
66. Nissen, S.E., Nicholls, S.J., Wolski, K., Rodes-Cabau, J., Cannon, C.P., Deanfield, J.E. et al. (2008) Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the stradivarius randomized controlled trial. JAMA 299: 1547-1560.
67. Norris, S.L., Zhang, X., Avenell, A., Gregg, E., Schmid, C.H. and Lau, J. (2005) Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. Cochrane Database Syst Rev: CD004096.
68. Onyike, C.U., Crum, R.M., Lee, H.B., Lyketsos, C.G. and Eaton, W.W. (2003) Is Obesity associated with major depression? Results from the Third National Health and Nutrition Examination Survey. Am J Epidemiol 158: 1139-1147.
69. Oster, G., Thompson, D., Edelsberg, J., Bird, A.P. and Colditz, G.A. (1999) Lifetime health and economic benefits of weight loss among obese persons. Am J Public Health 89: 1536-1542.
70. Padwal, R., Kezouh, A., Levine, M. and Etminan, M. (2007 a) Long-term persistence with orlistat and sibutramine in a population-based cohort. Int J Obes (Lond) 31: 1567-1570.
71. Padwal, R., Li, S.K. and Lau, D.C. (2003) Long-term pharmacotherapy for obesity and overweight Cochrane Database Syst Rev: CD004094.
72. Padwal, R.S. and Majumdar, S.R. (2007 b) Drug treatments for obesity: orlistat, sibutramine, and rimonabant. Lancet 369: 71-77.
73. Pagotto, U., Marsicano, G., Cota, D., Lutz, B. and Pasquali, R. (2006) The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 27: 73-100.
74. Pi-Sunyer, F.X., Aronne, L.J., Heshmati, H.M., Devin, J. and Rosenstock, J. (2006) Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 295: 761-775.
75. Pischon, T., Girman, C.J., Hotamisligil, G.S., Rifai, N., Hu, F.B. and Rimm, E.B. (2004) Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 291: 1730-1737.
76. Porter, J.A., Raebel, M.A., Conner, D.A., Lanty, F.A., Vogel, E.A., Gay, E.C. et al. (2004) The long-term outcomes of sibutramine effectiveness on weight (lose weight) study: evaluating the role of drug therapy within a weight management program in a group-model health maintenance organization. Am J Manag Care 10: 369-376.
77. Reinberg, S. (2007) FDA OKs 1st over-the-counter weight-loss drug, washingtonpost.com, 8 February 2007. Accessed on 4 June 2008.
78. Rippe, J.M., Crossley, S. and Ringer, R. (1998) Obesity as a chronic disease: modern medical and lifestyle management. J Am Diet Assoc 98: S9-15.
79. Rosenstock, J., Iranmanesh, A. and Hollander, P.A. (2007) Improved glycemic control with weight loss plus beneficial effects on atherogenic dyslipidemia with rimonabant in drug-naive type 2 diabetes: the SERENADE trial (abstract). Diabetes 56(Suppl. 1): A49-A50.
80. Rossner, S., Sjostrom, L., Noack, R., Meinders, A.E. and Noseda, G. (2000) Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 8: 49-61.
81. Rucker, D., Padwal, R., Li, S.K., Curioni, C. and Lau, D.C. (2007) Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 335: 1194-1199.
82. Sanchez-Reyes, L., Fanghanel, G., Yamamoto, J., Martinez-Rivas, L., Campos-Franco, E. and Berber, A. (2004) Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial. Clin Ther 26: 1427-1435.
83. Sari, R., Balci, M.K., Cakir, M., Altunbas, H. and Karayalcin, U. (2004) Comparison of efficacy of sibutramine or orlistat versus their combination in obese women. Endocr Res 30: 159-167.
84. Sauerland, S., Angrisani, L., Belachew, M., Chevallier, J.M., Favretti, F., Finer, N. et al. (2005) Obesity surgery: evidence-based guidelines of the European Association for Endoscopic Surgery (EAES). Surg Endosc 19: 200-221.
85. Scheen, A.J., Finer, N., Hollander, P., Jensen, M.D. and van Gaal, L.F. (2006) Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 368: 1660-1672.
86. Schindler, C. (2007) The metabolic syndrome as an endocrine disease: is there an effective pharmacotherapeutic strategy optimally targeting the pathogenesis? Ther Adv Cardiovasc Dis 1: 7-26.
87. Schindler, C., Siegert, J. and Kirch, W. (2008) Physical activity and cardiac performance - how important is cardiorespiratory fitness in childhood? J Public Health 16: 215-219.
88. Scholze, J., Grimm, E., Herrmann, D., Unger, T. and Kintscher, U. (2007) Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) Study. Circulation 115: 1991-1998.
89. Sever, P.S., Poulter, N.R., Dahlof, B. and Wedel, H. (2005) Different time course for prevention of coronary and stroke events by atorvastatin in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid-Lowering Arm (ASCOT-LLA). Am J Cardiol 96: 39F-44F.
90. Sharma, A.M., Bramlage, P. and Kirch, W. (2005) Antihypertensive effect of irbesartan and predictors of response in obesity-associated hypertension: a prospective, open-label study. Clin Drug Investig 25: 765-776.
91. Sharma, A.M., Pischon, T., Hardt, S., Kunz, I. and Luft, F.C. (2001) Hypothesis: beta-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension 37: 250-254.
92. Shekelle, P.G., Hardy, M.L., Morton, S.C., Maglione, M., Mojica, W.A., Suttorp, M.J. et al. (2003) Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA 289: 1537-1545.
93. Siepmann, M. and Kirch, W. (1998) Orlistat. Ein neues Medikament zur Adipositastherapie. Arzneimitteltherapie 16: 302-304.
94. Simes, R.J., Marschner, I.C., Hunt, D., Colquhoun, D., Sullivan, D., Stewart, R.A. et al. (2002) Relationship between lipid levels and clinical outcomes in the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Trial: to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation 105: 1162-1169.
95. Sjostrom, L., Lindroos, A.K., Peltonen, M., Torgerson, J., Bouchard, C., Carlsson, B. et al. (2004) Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 351: 2683-2693.
96. Sjostrom, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H.P. et al. (1998) Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 352: 167-172.
97. Snow, V., Barry, P., Fitterman, N., Qaseem, A. and Weiss, K. (2005) Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med 142: 525-531.
98. Spranger, J., Kroke, A., Mohlig, M., Bergmann, M.M., Ristow, M., Boeing, H. et al. (2003) Adiponectin and protection against type 2 diabetes mellitus. Lancet 361: 226-228.
99. Tong, P.C., Lee, Z.S., Sea, M.M., Chow, C.C., Ko, G.T., Chan, W.B. et al. (2002) The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese chinese subjects with or without type 2 diabetes. ArchInternMed 162: 2428-2435.
100. Torgerson, J.S., Hauptman, J., Boldrin, M.N. and Sjostrom, L. (2004) Xenical in the Prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct t lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27: 155-161.
101. Torp-Pedersen, C., Caterson, I., Coutinho, W., Finer, N., van Gaal, L., Maggioni, A. et al. (2007) Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. EurHeart J 28: 2915-2923.
102. van Gaal, L.F., Rissanen, A.M., Scheen, A.J., Ziegler, O. and Rossner, S. (2005) Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe Study. Lancet 365: 1389-1397.
103. Vettor, R., Serra, R., Fabris, R., Pagano, C. and Federspil, G. (2005) Effect of sibutramine on weight management and metabolic control in type 2 diabetes: a meta-analysis of clinical studies. Diabetes Care 28: 942-949.
104. Wadden, T.A. (1993) Treatment of obesity by moderate and severe caloric restriction. Results of clinical research trials. Ann Intern Med 119: 688-693.
105. Wadden, T.A., Berkowitz, R.I., Sarwer, D.B., Prus-Wisniewski, R. and Steinberg, C. (2001) Benefits of lifestyle modification in the pharmacologic treatment of obesity: a randomized trial. Arch Intern Med 161: 218-227.
106. Wadden, T.A., Berkowitz, R.I., Womble, L.G., Sarwer, D.B., Arnold, M.E. and Steinberg, C.M. (2000) Effects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obes Res 8: 431-437.
107. Wagner, N., Meusel, D. and Kirch, W. (2005) Nutrition education for children - results and perspectives. J Public Health 13: 102-110.
108. Weigle, D.S. (2003) Pharmacological therapy of obesity: past, present, and future. J Clin Endocrinol Metab 88: 2462-2469.
109. WHO. (2006) Obesity and overweight. WHO Fact Sheet N 311, September 2006. Available at:
110. WHO/Europe ( 2005) The challenge of obesity in the WHO European Region. Fact Sheet Euro/13/05 Copenhagen, Bucharest, 12 September 2005. Available at:
111. Williams, G. (2007) Orlistat over the counter. BMJ 335: 1163-1164.
112. Wirth, A. and Krause, J. (2001) Long-term weight loss with sibutramine: a randomized controlled trial. JAMA 286: 1331-1339.
113. Zhi, J., Melia, A.T., Eggers, H., Joly, R. and Patel, I.H. (1995) Review of Limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol 35: 1103-1108.
114. Zhi, J., Moore, R., Kanitra, L. and Mulligan, T.E. (2002) Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects. J Clin Pharmacol 42: 1011-1019.
115. Zhi, J., Moore, R., Kanitra, L. and Mulligan, T.E. (2003) Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers. J Clin Pharmacol 43: 428-435.